{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-001915","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.584882+00:00","generated_at":"2026-06-25T18:31:21.570302+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Entera Bio Q1 net loss $3.8M ($0.13/shr); cash $20.1M, expects funding into Q4 2022","bullets":["Revenue $68K from Amgen R&D services, down from $157K YoY; operating expenses $3.8M vs $2.4M.","Cash $20.1M at March 31, 2022 (vs $24.9M Dec 31); expects to fund operations into Q4 2022.","EB613 (oral PTH for osteoporosis): FDA completed CMC review; Phase 3 trial design underway.","Market study: >15M U.S. osteoporosis patients, 75% untreated; clinicians favor oral anabolic.","EB612 hypoparathyroidism: orphan drug status; working on improved formulation for next trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-001915","json":"https://secwatch.observer/filing/0001178913-22-001915.json","markdown":"https://secwatch.observer/filing/0001178913-22-001915.md","text":"https://secwatch.observer/filing/0001178913-22-001915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322001915/0001178913-22-001915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891322001915/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:31:21.570302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}